[Treatment of extrasystoles using a new oral anti-arrhythmic agent Aprindine].
D000293:Adolescent; D000328:Adult; D000368:Aged; D001073:Aprindine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005117:Cardiac Complexes, Premature / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D004562:Electrocardiography; D001068:Feeding and Eating Disorders / Q000139:chemically induced; D005260:Female; D006801:Humans; D007192:Indenes / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000188:drug therapy; D009325:Nausea / Q000139:chemically induced; D013614:Tachycardia, Paroxysmal / Q000188:drug therapy; D014202:Tremor / Q000139:chemically induced; D014717:Vertigo / Q000139:chemically induced
D007192:Indenes; D001073:Aprindine
Behandlung von Extrasystolien mit einem neuen peroralen Antiarrhythmikum (Aprindine)